|
| Press Releases |
|
 |
|
| Wednesday, July 10, 2019 |
|
|
Eisai Center for Genetics Guided Dementia Discovery Commences Full-Scale Operation Toward Innovative Dementia Treatments With New Drug Discovery Approach in Cambridge, Massachusetts |
| Eisai Co., Ltd. has announced that the Eisai Center for Genetics Guided Dementia Discovery (G2D2), a new exploratory research facility in Cambridge, Massachusetts, U.S., held its opening ceremony and has begun full-scale research activities. more info >> |
|
| Monday, July 8, 2019 |
|
|
Eisai Enters Into Collaboration Research Agreement With University of Dundee on Targeted Protein Degradation Toward Cancer Drug Discovery |
| Eisai Co.,Ltd. has entered into a collaboration research agreement with the University of Dundee in Scotland, UK, regarding Proteolysis Targeting Chimeras (PROTACs)(1) toward drug discovery in oncology area. more info >> |
|
| Tuesday, June 18, 2019 |
|
|
Eisai: Total Synthesis and Nonclinical Study Results of a Novel Anticancer Drug Candidate E7130 |
| Eisai Co., Ltd. announced today that a joint research group including scientists from Eisai and Professor Yoshito Kishi's group of Harvard University has achieved a total synthesis and obtained results of nonclinical studies of the novel compound, E7130, derived from total synthesis of halichondrin. more info >> |
|
|
Eisai to Present Latest Data on Perampanel at 33rd International Epilepsy Congress |
| Eisai Co., Ltd. announced today that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 33rd International Epilepsy Congress (IEC) to be held from June 22 to 26, 2019 in Bangkok, Thailand. more info >> |
|
| Wednesday, May 29, 2019 |
|
|
Eisai to Present Latest Data on Lemborexant including Integrated Analysis of Phase III Clinical Studies at 33rd Annual Sleep Meeting |
| Eisai Co.,Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced that latest information on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleepwake disorders, including insomnia and Irregular Sleep-Wake Rhythm Disorder (ISWRD) will be presented at the 33rd Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2019), from June 8 to 12 in San Antonio, Texas, the United States. more info >> |
|
| Friday, May 17, 2019 |
|
|
"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets |
| Eisai Co., Ltd. announced today that Eisai has received approval from "Science Based Targets (SBT) Initiative" for Eisai's mid and long-term targets for greenhouse gas (GHG) reduction. more info >> |
|
| Thursday, May 16, 2019 |
|
|
Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting |
| Major poster presentations at this year's meeting include highlights of the latest data from an ongoing Phase I clinical study investigating Eisai's first ADC MORAb-202 in patients with solid tumors in Japan. more info >> |
|
| Friday, May 10, 2019 |
|
|
Eisai Enters Into Licensing Agreement With Medac Concerning Anti-Rheumatic Agent Methotrexate Subcutaneous Injection in Japan |
| Under the agreement, Eisai will obtain exclusive rights to market MTX subcutaneous injection in Japan. Medac will submit a manufacturing and marketing authorization application for the product after conducting a clinical study in Japan. more info >> |
|
|
Eisai: Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401 |
| These studies will be conducted with funding from various sources including the United States National Institute on Aging (NIA), part of the National Institutes of Health, and Eisai. more info >> |
|
| Thursday, May 9, 2019 |
|
|
Eisai and Allm Enter Into Capital and Business Alliance Agreement for ICT Healthcare Solutions |
| Eisai Co., Ltd. and Allm Inc. have entered into a capital and business alliance agreement for ICT digital health solutions in various areas as well as regional medical treatment and care. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
CALB (3931.HK) Included in the Hang Seng Composite Index
Feb 23, 2025 21:59 HKT/SGT
|
|
|
Four HK designer labels shine at London Fashion Week
Feb 22, 2025 22:56 HKT/SGT
|
|
|
Dollamur Announces United World Wrestling Approval Through 2028
Feb 22, 2025 22:54 HKT/SGT
|
|
|
Yashaa Global Capital Secures Financial Services Permission to Establish a Global Sports VC Fund
Feb 22, 2025 20:11 HKT/SGT
|
|
|
AsiaMedic and Sunway launch new Medical Diagnostic Imaging Centre in Novena 
Feb 22, 2025 18:00 HKT/SGT
|
|
|
Soligenix's Leadership Aims to Drive Growth in Rare Disease Markets in 2025 and 2026
Feb 22, 2025 4:50 JST
|
|
|
Alexis Mc Allister Announces as Jeton's Latest Brand Ambassador
Feb 21, 2025 23:00 HKT/SGT
|
|
|
NaaS Technology Launches $10 Million Share Repurchase Plan Boosting Market Confidence
Feb 21, 2025 21:09 HKT/SGT
|
|
|
Honda Receives Highest Ranking of 3 Stars as Part of FIA Road Safety Index, Tool for Organizations and Companies to Measure Their Road Safety Footprint
Feb 21, 2025 19:40 JST
|
|
|
Carl Zeiss Honors EuroEyes International for Exceptional Milestone in AT LISA(R) Trifocal Lens Implantations
Feb 21, 2025 18:29 HKT/SGT
|
|
|
Honda Partners with United Nations Road Safety Fund (UNRSF) to Work Toward Reduction of Fatalities from Traffic Collisions
Feb 21, 2025 19:11 JST
|
|
|
Mitsubishi Logistics Corporation, Mitsubishi Corporation, and Yourstand Inc. Advancing Completely CO2-Free Electrification of Pharmaceutical Transportation
Feb 21, 2025 15:01 JST
|
|
|
NEC Innovation Challenge awards Canada's Prevu3D Inc. with the NEC Award and NOFF Award
Feb 21, 2025 14:39 JST
|
|
|
NEC Develops Near Real-time RIC for High Performance 5G vRAN
Feb 21, 2025 12:00 JST
|
|
|
Igloo kicks off 2025 with Multi-market Partnership Wins and Chief Distribution Officer Appointment
Feb 21, 2025 09:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
